Tema Etfs LLC Acquires Shares of 61,503 Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Tema Etfs LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 61,503 shares of the biotechnology company's stock, valued at approximately $1,156,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $38,000. Van ECK Associates Corp increased its position in shares of Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 1,250 shares during the last quarter. KBC Group NV boosted its holdings in shares of Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after buying an additional 1,644 shares during the period. Envestnet Portfolio Solutions Inc. bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $205,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ARWR has been the subject of several research reports. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Wall Street Zen raised Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. B. Riley reaffirmed a "buy" rating and issued a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, Citigroup decreased their target price on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $42.13.

Insider Activity

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 133,333 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the completion of the sale, the chief executive officer now owns 3,773,802 shares in the company, valued at approximately $64,230,110.04. The trade was a 3.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 275,880 shares of company stock worth $4,034,037 in the last three months. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Trading Down 2.0%

Shares of NASDAQ:ARWR traded down $0.31 during mid-day trading on Friday, hitting $15.08. The company had a trading volume of 292,835 shares, compared to its average volume of 1,495,495. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $30.41. The firm has a fifty day moving average price of $13.32 and a 200 day moving average price of $17.70. The company has a market capitalization of $2.08 billion, a PE ratio of -2.91 and a beta of 0.89.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million during the quarter, compared to the consensus estimate of $116.27 million. During the same period last year, the firm posted ($1.02) earnings per share. As a group, research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.